BETTER DATA BETTER TREATMENT
Liquid Biopsy Chemotherapy Drug Resistance screening offers the primary care physician actionable insight into each individual undergoing treatment.
With up to 90% of cancer mortality linked to drug resistance, better data means better treatment from the start.
*The report above is a simplified version of the Axaitech clinical report for illustrative purposes only.
WHY LIQUID BIOPSY?
Liquid biopsy screens provide several advantages over traditional tissue biopsies, most notably it's comparatively low invasiveness.
For patients for which tissue-based testing is not appropriate or is not available, liquid biopsy can provide a safe alternative test for determining targeted therapy and monitoring treatment efficacy and disease progression.
HOW IT WORKS
Patients diagnosed with any form of cancer submit a blood sample, authorized by their primary care physician, collected at any convenient location. No invasive surgeries, no delays.
We analyze the patient's DNA, screening for 57 unique, clinically validated markers associated with chemotherapy drug resistance.
We provide a report to the primary care physician outlining the complete genomic profile relating to chemotherapy drug resistance, with actionable insights to help shape the treatment plan of the individual.
Axaitech was founded as Africa's answer to the global liquid biopsy movement in cancer treatment. Our focus is on providing the most actionable insight possible so that oncologists can make more informed decisions regarding their patients treatment. Better data means better treatment and ultimately, better quality of life.
Our vision is to provide the people of Africa with bleeding edge cancer treatment technologies from a uniquely African perspective. Our genomic profiling services and research divisions focus on creating world class, accessible technology platforms.
Axaitech offers a complete pan-cancer chemotherapy drug resistance liquid biopsy screen. Leveraging the world's leading wet lab and bioinformatics solutions we are able to bring the future of cancer treatment to Africa. Our analysis is carried out in an ISO accredited laboratory and annotated using a CE IVD-certified and HIPAA-compliant platform.
REQUEST A CONSULT
To schedule a meeting with one of our product consultants, please fill in your contact details.*
* Please note that due to HPCSA regulations all genetic screening tests must be performed under the guidance of a certified medical practitioner or genetic counselor.